<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567136</url>
  </required_header>
  <id_info>
    <org_study_id>130126</org_study_id>
    <nct_id>NCT02567136</nct_id>
  </id_info>
  <brief_title>Imaging Biomarkers in ALS</brief_title>
  <official_title>A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if we are able to find one or more biomarkers of&#xD;
      Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic&#xD;
      resonance imaging (MRI) scans at different levels, 3 tesla (3T) and 7 tesla (7T). A biomarker&#xD;
      is a measurable characteristic that can be used as an indicator of a particular disease&#xD;
      state. Identifying biomarkers of a disease can lead to a better understanding of the disease&#xD;
      as well as improved treatments. This study will enroll patients with ALS, PLS, and healthy&#xD;
      controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of neurochemical concentrations and Diffusion Tensor Imaging (DTI) parameters between ALS subjects and age-matched normal subjects.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amyotrophic Lateral Sclerosis</arm_group_label>
    <description>Patients with ALS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy control volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll ALS patients seeking care at the University of Minnesota and&#xD;
        age-matched healthy control volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21 to 75 years of age inclusive.&#xD;
&#xD;
          -  Willing and able to give signed informed consent that has been approved by the&#xD;
             Institutional Review Board (IRB).&#xD;
&#xD;
        ALS patients:&#xD;
&#xD;
          -  A clinical diagnosis of possible, laboratory-supported probable, probable, or definite&#xD;
             ALS, according to a modified El Escorial criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,&#xD;
             etc).&#xD;
&#xD;
          -  Clinically significant history of unstable medical illness (unstable angina, advanced&#xD;
             cancer, etc) over the last 30 days.&#xD;
&#xD;
          -  Inability to undergo MRI scanning, including but not limited to unable to remain still&#xD;
             in an MRI scanner for more than 30 minutes, claustrophobia, presence of paramagnetic&#xD;
             substances or pacemakers in body, weight over 300 lbs, or in the opinion of the&#xD;
             investigator, if there is a strong likelihood that the subject would not be able to&#xD;
             lie flat comfortably for 75-90 minutes.&#xD;
&#xD;
          -  The subject requires assistance to ambulate OR climb stairs, unless in the opinion of&#xD;
             the investigator, and based upon the subject's rate of disease progression, the&#xD;
             subject is likely to be able to participate in the MRI screening 12 months after&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Walk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

